AZD0466

DRUG3 trials

Sponsors

AstraZeneca

Conditions

Advanced Solid TumorsHaematological MalignanciesHematologic MalignanciesLymphomaMultiple MyelomaNon-Hodgkin Lymphoma

Phase 1

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

TerminatedNCT04214093

AstraZenecaAdvanced Solid Tumors, Hematologic Malignancies, Lymphoma +1

Start: 2019-12-16End: 2021-06-18Updated: 2023-08-02

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

TerminatedNCT04865419

AstraZenecaHaematological Malignancies

Start: 2021-06-11End: 2023-08-08Updated: 2025-06-15

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

TerminatedNCT05205161

AstraZenecaNon-Hodgkin Lymphoma

Start: 2022-07-05End: 2023-08-17Updated: 2025-01-07

Related Papers

Abstract CT146: AZD0466 in patients with advanced non-Hodgkin lymphoma: Efficacy and safety in an open-label phase 1 trial

Cancer Research2024-04-05

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Blood2023-11-022 citations

P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

HemaSphere2023-08-01

Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models

Cancer Research2023-04-04

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Blood2022-11-151 citations

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

Blood2021-11-056 citations